Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 31
Filter
1.
J Pediatr Psychol ; 49(6): 383-391, 2024 Jun 13.
Article in English | MEDLINE | ID: mdl-38366576

ABSTRACT

OBJECTIVES: Neurofibromatosis type 1 (NF1) is a genetic cancer predisposition syndrome that can impact multiple organ systems and is associated with plexiform neurofibroma tumors, requiring care from birth through adulthood. Adolescents and young adults (AYAs) with NF1 face several barriers to transition from pediatric to adult care. This cross-sectional study aimed to assess transition readiness in this population and to evaluate relationships between specific NF1 symptoms and transition readiness. METHODS: AYAs (aged 16-24) enrolled in existing studies related to NF1 were eligible. AYAs and their parents completed measures of transition readiness (Transition Readiness Assessment Questionnaire version 4 [TRAQ-4]), and AYAs also completed a transition readiness interview (UNC TRxANSITION). RESULTS: Thirty-eight AYAs (mean age = 19.95 ± 2.68 years) participated in the study. Average TRAQ scores indicated that AYAs were still learning Self-Management skills (M = 3.37, SD = 1.08) and Self-Advocacy skills (M = 3.98, SD = 0.67). Older AYAs had higher TRAQ scores for Self-Management (r = 0.70, p < .001) and Self-Advocacy (r = 0.41, p = .011) than younger AYAs. Parents and AYAs had similar TRAQ scores. About one third of AYAs (37.8%, n = 14) expressed uncertainty about how NF1 might affect them in the future. The remaining AYAs mostly expressed concerns regarding tumor growth, pain, or cancer. CONCLUSIONS: In this small study, preliminary findings suggest that AYAs with NF1 express confidence in many areas of transition readiness but continue to require support, particularly with Self-Management skills. Given the gaps in understanding of future health risks, AYAs with NF1 would benefit from early assessment, psychoeducation, and support for transition readiness to adult care.


Subject(s)
Neurofibroma, Plexiform , Neurofibromatosis 1 , Transition to Adult Care , Adolescent , Female , Humans , Male , Young Adult , Cross-Sectional Studies , Neurofibroma, Plexiform/psychology , Neurofibroma, Plexiform/therapy , Neurofibromatosis 1/psychology , Neurofibromatosis 1/therapy , Surveys and Questionnaires
2.
Curr Med Res Opin ; 40(4): 723-731, 2024 04.
Article in English | MEDLINE | ID: mdl-38404173

ABSTRACT

OBJECTIVES: The objectives of this study were to retrospectively investigate the patient characteristics, treatment patterns, healthcare resource utilization (HCRU), and healthcare costs related to management of neurofibromatosis type 1 (NF1) in Japan. METHODS: Cohorts of NF1 patients with or without plexiform neurofibromas (PN) were identified from the Medical Data Vision database in 2008-2019. Baseline characteristics, NF1 medications, HCRU, and associated costs were assessed using descriptive statistics. All-cause HCRU and costs following the first confirmed NF1 diagnosis date were analyzed per patient per year (PPPY) in Japanese Yen (JPY) and United States Dollar (USD). RESULTS: A total of 4394 NF1 patients without PN and 370 NF1 patients with PN were identified. The mean age was 35.0 and 36.9 years, respectively. The proportion of patients with PN treated with medications was higher than that in patients without PN (except for antirheumatic/immunologic agents). Analgesics/non-steroidal anti-inflammatory drugs were the most frequently prescribed NF1 medications (44.3% and 56.0% in patients without and with PN, respectively), followed by inpatient prescriptions of opioids/opioid-like agents (17.8% and 27.6%, respectively). Inpatient admissions accounted for the highest costs in both cohorts with the average cost PPPY being JPY 2,133,277 (USD 19,861) for patients without PN and JPY 1,052,868 (USD 9802) for patients with PN. CONCLUSIONS: NF1 is treated primarily with supportive care with analgesics/non-steroidal anti-inflammatory drugs being the most frequently prescribed NF1 medications in Japan. Findings underscored the unmet need and substantial economic burden among patients with NF1 and highlighted the need for new treatment options for patients with this disease.


Subject(s)
Neurofibroma, Plexiform , Neurofibromatosis 1 , Humans , Adult , Neurofibromatosis 1/therapy , Neurofibromatosis 1/drug therapy , Neurofibroma, Plexiform/diagnosis , Neurofibroma, Plexiform/therapy , Japan/epidemiology , Retrospective Studies , Health Care Costs , Analgesics/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
3.
Curr Oncol Rep ; 25(12): 1409-1417, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37906356

ABSTRACT

Neurofibromatosis type I (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis represent a diverse group of genetic tumor predisposition syndromes with a shared feature of tumors affecting the peripheral nerve sheaths. PURPOSE OF REVIEW: Many advancements have been made in understanding the biologic underpinnings of these conditions, and in 2016 the first drug was approved by the FDA to treat pediatric symptomatic unresectable plexiform neurofibromas. RECENT FINDINGS: Mek inhibitors have provided a much-needed therapeutic avenue for NF1 patients with unresectable plexiform neurofibromas (PN), both for reduction of tumor bulk and for improvement in symptoms. Selumetinib is the first FDA approved drug for PN, but is only approved for children. Some research suggests that alternative Mek inhibitors and other mixed tyrosine kinase inhibitors may have better efficacy in adults. Vascular endothelial growth factor (VEGF) inhibitor bevacizumab can prolong hearing and delay the need for surgery in NF2 patients with bilateral vestibular schwannomas. This article provides an update regarding considerations and approaches when treating the tumors associated with the neurofibromatoses (NF), including risk and prognosis metrics, clinical trial results, surgical techniques, and radiation therapy recommendations.


Subject(s)
Neurofibroma, Plexiform , Neurofibromatoses , Neurofibromatosis 1 , Peripheral Nervous System Neoplasms , Adult , Humans , Child , Neurofibroma, Plexiform/complications , Neurofibroma, Plexiform/therapy , Vascular Endothelial Growth Factor A , Neurofibromatoses/complications , Neurofibromatoses/therapy , Neurofibromatoses/diagnosis , Neurofibromatosis 1/complications , Neurofibromatosis 1/therapy , Genetic Predisposition to Disease , Protein Kinase Inhibitors/therapeutic use , Mitogen-Activated Protein Kinase Kinases
4.
Am J Med Genet A ; 188(6): 1723-1727, 2022 06.
Article in English | MEDLINE | ID: mdl-35178860

ABSTRACT

We report on the location, symptoms, and management of plexiform neurofibroma (PN) in children with Neurofibromatosis Type 1 (NF1) attending the 2 National Complex Neurofibromatosis 1 Services at Guy's and St. Thomas' NHS Foundation Trust, London and St Mary's Hospital, Manchester. Retrospective data collection was performed from patient chart reviews from April 2018 to April 2019. There were 127 NF1 patients with PN, age range 0.8-17.0, mean age was 9.9 years (SD ± 4.2 years). The main location of the PN was craniofacial in 35%, and limb in 19%. Disfigurement was present in 57%, pain in 28%, impairment of function in 23%, and threat to function in 9% of children. Fifty-four percent of patients were managed conservatively, 28% surgically, and 19% are either taking or due to start a mitogen-activated protein kinase kinase (MEK) inhibitor (selumetinib or trametinib), either through a clinical trial or compassionate usage scheme. This national study provides a comprehensive overview of the management of children with PN in an era where new therapies (MEK inhibitors) are becoming more widely available. We anticipate that there will be a shift to more patients receiving MEK inhibitor therapy and combination therapy (surgery and MEK inhibitor) in the future.


Subject(s)
Neurofibroma, Plexiform , Neurofibromatosis 1 , Adolescent , Child , Child, Preschool , Humans , Infant , Mitogen-Activated Protein Kinase Kinases , Neurofibroma, Plexiform/epidemiology , Neurofibroma, Plexiform/therapy , Neurofibromatosis 1/complications , Neurofibromatosis 1/therapy , Protein Kinase Inhibitors/therapeutic use , Retrospective Studies
5.
Article in English | MEDLINE | ID: mdl-34379966

ABSTRACT

Neurofibromatosis type 1, the most common phakomatoses, can present with a host of signs and symptoms, usually involving the skin and the peripheral nervous system. It is characterized by a mutation in the neurofibromatosis type 1 gene on chromosome 17q11.2 that codes for the protein neurofibromin. Neurofibromin acts as a tumor suppressor gene by inhibiting rat sarcoma (Ras) activity and its deficiency leads to increased Ras activity, cellular proliferation and tumor formation. This review was conducted to analyze the various targeted therapies at the genetic and molecular level employed to manage the tumors and other clinical presentations associated with neurofibromatosis type 1. Twenty-eight studies of treatment modalities for the conditions associated with neurofibromatosis and which involved either targeted gene therapy or molecular level therapies, including the latest advances, were included in this review. Mitogen-activated protein kinase kinase inhibition, mammalian target of Rapamycin inhibition and Tyrosine kinase inhibition, represent some of the newer treatment options in this category. Although there are a number of trials for providing therapeutic options at the genetic and molecular level for the various physical and psychological morbidities associated with neurofibromatosis type 1, most of them are in the preclinical stage. Increased clinical trials of the molecules and gene therapies could significantly help in managing the various chronic and sometimes, life-threatening conditions associated with neurofibromatosis 1 and these will probably represent the preferred treatment direction of the future.


Subject(s)
Molecular Targeted Therapy , Neurofibromatosis 1/therapy , Cognitive Dysfunction/etiology , Fracture Healing/genetics , Humans , Nerve Sheath Neoplasms/etiology , Nerve Sheath Neoplasms/therapy , Neurofibroma, Plexiform/etiology , Neurofibroma, Plexiform/therapy , Neurofibromatosis 1/complications , Optic Nerve Glioma/etiology , Optic Nerve Glioma/therapy
6.
Curr Med Res Opin ; 37(9): 1555-1561, 2021 09.
Article in English | MEDLINE | ID: mdl-34218725

ABSTRACT

OBJECTIVES: The objectives of this study were to describe the characteristics and initial treatment patterns, healthcare resource use (HCRU), and costs of patients newly diagnosed with neurofibromatosis type 1 (NF1)-related plexiform neurofibromas (PN). METHODS: This was a retrospective study of individuals enrolled in the IBM MarketScan Multi-State Medicaid database from 1 October 2014 to 31 December 2017. Patients aged ≤18 years at the index date (first diagnosis of NF1 or PN, whichever occurred later) with at least 1 ICD-10-CM diagnosis code for both NF1 and PN were included. All-cause HCRU and the associated direct costs during the follow-up period were calculated per patient per year (PPPY) in 2018 USD. RESULTS: A total of 383 patients were included with a mean follow-up of 448 days. Most patients were diagnosed by a specialist (63.5%). During the follow-up period, pain medications were used by 58.5% of patients, 25.1% were treated with chemotherapy, 7.1% received surgery for PN, 1.6% received MEK inhibitors, and 0.8% received radiation. Mean PPPY inpatient, outpatient, ER, pharmacy, and other visits were 1.4, 17.3, 1.6, 13.6, and 25.8, respectively. Mean ± SD (median) total PPPY healthcare costs were $17,275 ± $61,903 ($2889), with total medical costs of $14,628 ± $56,203 ($2334) and pharmacy costs of $2646 ± $13,303 ($26). CONCLUSIONS: This study showed that many pediatric patients newly diagnosed with NF1 and PN were initially treated with supportive care only, highlighting a substantial unmet medical need. This study also highlights the considerable economic burden among patients with NF1 and PN.


Subject(s)
Health Care Costs , Neurofibroma, Plexiform , Neurofibromatosis 1 , Child , Humans , Medicaid , Neurofibroma, Plexiform/economics , Neurofibroma, Plexiform/therapy , Neurofibromatosis 1/economics , Neurofibromatosis 1/therapy , Retrospective Studies , United States
11.
Sci Data ; 5: 180106, 2018 06 12.
Article in English | MEDLINE | ID: mdl-29893754

ABSTRACT

Neurofibromatosis type I (NF1) is an autosomal dominant genetic condition characterized by peripheral nervous system tumors (PNSTs), including plexiform neurofibromas (pNFs) that cause nerve dysfunction, deformity, pain damage to adjacent structures, and can undergo malignant transformation. There are no effective therapies to prevent or treat pNFs. Drug discovery efforts are slowed by the 'benign' nature of the Schwann cells that are the progenitor cells of pNF. In this work we characterize a set of pNF-derived cell lines at the genomic level (via SNP Arrays, RNAseq, and Whole Exome- Sequencing), and carry out dose response-based quantitative high-throughput screening (qHTS) with a collection of 1,912 oncology-focused compounds in a 1536-well microplate cell proliferation assays. Through the characterization and screening of NF1-/-, NF1+/+ and NF1+/- Schwann cell lines, this resource introduces novel therapeutic avenues for the development for NF1 associated pNF as well as all solid tumors with NF1 somatic mutations. The integrated data sets are openly available for further analysis at http://www.synapse.org/pnfCellCulture.


Subject(s)
Gene Expression Profiling , Neurofibromatosis 1 , Schwann Cells , Antineoplastic Agents/therapeutic use , Cell Line, Tumor , Humans , Neurofibroma, Plexiform/genetics , Neurofibroma, Plexiform/pathology , Neurofibroma, Plexiform/therapy , Neurofibromatosis 1/genetics , Neurofibromatosis 1/pathology , Neurofibromatosis 1/therapy
12.
Arch Pediatr ; 24(10): 986-990, 2017 Oct.
Article in French | MEDLINE | ID: mdl-28870819

ABSTRACT

Neurofibromatosis type 1 (NF1) is a frequent autosomal dominant genetic disorder that predisposes to the development of benign and malignant tumors. Mutation of the NF1 gene affects the RAS-MAPK signaling pathway and leads to a dysfunction in cell proliferation and induces tumor development. Epidemiology of cancer in children with NF1 is very different from the general pediatric population, which requires regular and specific monitoring. Neurofibroma is the most frequent benign tumor. It can be very invalidating depending on the size and location of the tumor. Currently, there is no specific treatment for these tumors. The most frequent malignancies in children with NF1 are leukemias, rhabdomyosarcomas, malignant peripheral nerve sheath tumors and gliomas. The treatment of these tumors should consider the risk of second cancers induced by radio- and chemotherapy. We report on the case of a 5-year-old boy with NF1 developing two tumors.


Subject(s)
Neoplasms, Multiple Primary , Neurofibroma, Plexiform , Neurofibromatosis 1 , Rhabdomyosarcoma , Child, Preschool , Humans , Male , Neoplasms, Multiple Primary/diagnosis , Neoplasms, Multiple Primary/therapy , Neurofibroma, Plexiform/diagnosis , Neurofibroma, Plexiform/therapy , Neurofibromatosis 1/diagnosis , Neurofibromatosis 1/therapy , Rhabdomyosarcoma/diagnosis , Rhabdomyosarcoma/therapy
13.
Ophthalmology ; 124(1): 123-132, 2017 01.
Article in English | MEDLINE | ID: mdl-27817916

ABSTRACT

TOPIC: Children and adults with neurofibromatosis type 1 (NF1), a common autosomal dominant condition, manifest a variety of ophthalmologic conditions. Plexiform neurofibromas (PNs) involving the eyelid, orbit, periorbital, and facial structures (orbital-periorbital plexiform neurofibroma [OPPN]) can result in significant visual loss in children. Equally important, OPPNs can cause significant alteration in physical appearance secondary to proptosis, ptosis, and facial disfigurement, leading to social embarrassment and decreased self-esteem. CLINICAL RELEVANCE: Although NF1 is a relatively common disease in which routine ophthalmologic examinations are required, no formal recommendations for clinical care of children with OPPNs exist. Although medical and surgical interventions have been reported, there are no agreed-on criteria for when OPPNs require therapy and which treatment produces the best outcome. METHODS: Because a multidisciplinary team of specialists (oculofacial plastics, pediatric ophthalmology, neuro-ophthalmology, medical genetics, and neuro-oncology) direct management decisions, the absence of a uniform outcome measure that represents visual or aesthetic sequelae complicates the design of evidence-based studies and feasible clinical trials. RESULTS: In September 2013, a multidisciplinary task force, composed of pediatric practitioners from tertiary care centers experienced in caring for children with OPPN, was convened to address the lack of clinical care guidelines for children with OPPN. CONCLUSIONS: This consensus statement provides recommendations for ophthalmologic monitoring, outlines treatment indications and forthcoming biologic therapy, and discusses challenges to performing clinical trials in this complicated condition.


Subject(s)
Eyelid Neoplasms/therapy , Neurofibroma, Plexiform/therapy , Neurofibromatosis 1/complications , Orbital Neoplasms/therapy , Child , Consensus , Delivery of Health Care, Integrated , Disease Management , Eyelid Neoplasms/pathology , Humans , Interdisciplinary Communication , Neurofibroma, Plexiform/pathology , Practice Guidelines as Topic
14.
Rev. neurol. (Ed. impr.) ; 64(supl.3): s13-s17, 2017. ilus, tab
Article in Spanish | IBECS | ID: ibc-163049

ABSTRACT

Introducción. El término «rasopatías» agrupa una serie de enfermedades que presentan mutaciones en genes que codifican las proteínas de la vía RAS/MAPK. Estas enfermedades incluyen la neurofibromatosis de tipo 1, el síndrome de Noonan, el síndrome de Legius, el síndrome LEOPARD, el síndrome de Costello y el síndrome cardiofaciocutáneo. La afectación de la vía RAS/MAPK no sólo aumenta la predisposición a desarrollar tumores, sino que también determina la presencia de anomalías fenotípicas y alteraciones en los procesos de aprendizaje. Objetivo. Revisar el papel del uso de estrategias terapéuticas con mecanismos de acción selectivo en las rasopatías. Desarrollo. El hecho de que la vía RAS participe en un tercio de las neoplasias ha motivado el desarrollo y el estudio de distintos fármacos a este nivel. Algunos de estos fármacos han sido probados en las rasopatías, principalmente en la neurofibromatosis de tipo 1. Analizamos el uso de distintos tratamientos antidiana: fármacos que actúan en los receptores de membrana, como los inhibidores de la tirosincinasa, en la vía mTOR o los inhibidores de MEK. Existe un potencial beneficio de estos últimos en estudios recientes realizados en distintas rasopatías. Conclusiones. Actualmente, gracias a los resultados de los primeros trabajos desarrollados con inhibidor de MEK basados principalmente en modelos animales, se están realizando múltiples ensayos clínicos prometedores (AU)


Introduction. The term «RASopathies» covers a series of diseases that present mutations in the genes that code for the proteins of the RAS/MAPK pathway. These diseases include neurofibromatosis type 1, Noonan syndrome, Legius syndrome, LEOPARD syndrome, Costello syndrome and cardiofaciocutaneous syndrome. Involvement of the RAS/MAPK pathway not only increases predisposition to develop tumours, but also determines the presence of phenotypic anomalies and alterations in learning processes. Aim. To review the use of therapeutic strategies with mechanisms that have a selective action on RASopathies. Development. The fact that the RAS pathway is involved in a third of all neoplasms has led to the development and study of different drugs at this level. Some of these pharmaceutical agents have been tested in RASopathies, mainly in neurofibromatosis type 1. Here we analyse the use of different antitarget treatments: drugs that act on the membrane receptors, such as tyrosine kinase inhibitors, in the mTOR pathway or MEK inhibitors. These latter have shown potential benefits in recent studies conducted on different RASopathies. Conclusions. Today, thanks to the results from the first studies conducted with MEK inhibitor based mainly on animal models, a number of promising clinical trials are being carried out (AU)


Subject(s)
Humans , Child , Mutagenesis/physiology , Genes, Neurofibromatosis 1/physiology , Neurofibromatosis 1/complications , Noonan Syndrome/complications , MAP Kinase Kinase Kinases/therapeutic use , TOR Serine-Threonine Kinases/therapeutic use , Protein-Tyrosine Kinases/therapeutic use , Neurofibroma, Plexiform/therapy , Antineoplastic Agents/therapeutic use , Nervous System Diseases/rehabilitation , Neurofibroma, Plexiform/complications , Mutagenesis, Site-Directed
15.
Neurology ; 87(7 Suppl 1): S13-20, 2016 Aug 16.
Article in English | MEDLINE | ID: mdl-27527645

ABSTRACT

OBJECTIVE: Plexiform neurofibromas (PNs) are complex, benign nerve sheath tumors that occur in approximately 25%-50% of individuals with neurofibromatosis type 1 (NF1). PNs that cause airway compromise or pulmonary dysfunction are uncommon but clinically important. Because improvement in sleep quality or airway function represents direct clinical benefit, measures of sleep and pulmonary function may be more meaningful than tumor size as endpoints in therapeutic clinical trials targeting airway PN. METHODS: The Response Evaluation in Neurofibromatosis and Schwannomatosis functional outcomes group reviewed currently available endpoints for sleep and pulmonary outcomes and developed consensus recommendations for response evaluation in NF clinical trials. RESULTS: For patients with airway PNs, polysomnography, impulse oscillometry, and spirometry should be performed to identify abnormal function that will be targeted by the agent under clinical investigation. The functional group endorsed the use of the apnea hypopnea index (AHI) as the primary sleep endpoint, and pulmonary resistance at 10 Hz (R10) or forced expiratory volume in 1 or 0.75 seconds (FEV1 or FEV0.75) as primary pulmonary endpoints. The group defined minimum changes in AHI, R10, and FEV1 or FEV0.75 for response criteria. Secondary sleep outcomes include desaturation and hypercapnia during sleep and arousal index. Secondary pulmonary outcomes include pulmonary resistance and reactance measurements at 5, 10, and 20 Hz; forced vital capacity; peak expiratory flow; and forced expiratory flows. CONCLUSIONS: These recommended sleep and pulmonary evaluations are intended to provide researchers with a standardized set of clinically meaningful endpoints for response evaluation in trials of NF1-related airway PNs.


Subject(s)
Clinical Trials as Topic/methods , Neurofibroma, Plexiform/therapy , Neurofibromatosis 1/therapy , Oscillometry/methods , Polysomnography/methods , Spirometry/methods , Humans , Lung/physiopathology , Neurofibroma, Plexiform/physiopathology , Neurofibromatosis 1/physiopathology , Sleep/physiology , Treatment Outcome
16.
Anticancer Res ; 35(12): 6813-8, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26637901

ABSTRACT

Neurofibromatosis type 1 (NF1) is an autosomal-dominant inherited disease affecting various parts of the body. Penetrance is almost complete but the phenotype varies considerably. Recently, mosaicism in NF1 has come into the focus of scientific interest. This report refers to a patient with orbitotemporal-confined neurofibromatosis who developed a rare skin tumor in the region.


Subject(s)
Neurofibroma, Plexiform/therapy , Neurofibromatosis 1/therapy , Orbital Neoplasms/therapy , Female , Humans , Middle Aged , Neurofibroma, Plexiform/pathology , Neurofibromatosis 1/pathology , Orbital Neoplasms/pathology
17.
Rev Stomatol Chir Maxillofac Chir Orale ; 116(4): 209-14, 2015 Sep.
Article in French | MEDLINE | ID: mdl-26194627

ABSTRACT

Type I neurofibromatosis (NF) is the most common autosomal dominant disease. It concerns one in 3000 births, the penetrance is close to 100% and 50% of new cases are de novo mutations (17q11.2 chromosome 17 location). Cranio-maxillofacial region is concerned in 10% of the cases, in different forms: molluscum neurofibroma, plexiform neurofibroma, cranio-orbital neurofibroma, parotido-jugal neurofibroma, cervical neurofibroma. These lesions have different prognosis depending on the craniofacial localization: ocular functional risk, upper airway compressive risk, nerve compression risk, aesthetic and social impact. The maxillofacial surgeon in charge of patients with type I NF should follow the patient from the diagnosis and organize the different surgical times in order to take care about the different issues: vital, functional and aesthetic. We describe the treatment of facial localizations of type 1 NF as it is done at the University Hospital of Lyon and at the Rhône-Alpes-Auvergne neurofibromatosis reference center.


Subject(s)
Head and Neck Neoplasms/therapy , Neurofibromatosis 1/therapy , Facial Neoplasms/diagnosis , Facial Neoplasms/therapy , Head and Neck Neoplasms/diagnosis , Humans , Neurofibroma, Plexiform/diagnosis , Neurofibroma, Plexiform/therapy , Neurofibromatosis 1/diagnosis , Orbital Neoplasms/pathology , Orbital Neoplasms/therapy , Plastic Surgery Procedures/methods , Skull Neoplasms/diagnosis , Skull Neoplasms/therapy
18.
Neurology ; 81(21 Suppl 1): S33-40, 2013 Nov 19.
Article in English | MEDLINE | ID: mdl-24249804

ABSTRACT

OBJECTIVE: Neurofibromatosis (NF)-related benign tumors such as plexiform neurofibromas (PN) and vestibular schwannomas (VS) can cause substantial morbidity. Clinical trials directed at these tumors have become available. Due to differences in disease manifestations and the natural history of NF-related tumors, response criteria used for solid cancers (1-dimensional/RECIST [Response Evaluation Criteria in Solid Tumors] and bidimensional/World Health Organization) have limited applicability. No standardized response criteria for benign NF tumors exist. The goal of the Tumor Measurement Working Group of the REiNS (Response Evaluation in Neurofibromatosis and Schwannomatosis) committee is to propose consensus guidelines for the evaluation of imaging response in clinical trials for NF tumors. METHODS: Currently used imaging endpoints, designs of NF clinical trials, and knowledge of the natural history of NF-related tumors, in particular PN and VS, were reviewed. Consensus recommendations for response evaluation for future studies were developed based on this review and the expertise of group members. RESULTS: MRI with volumetric analysis is recommended to sensitively and reproducibly evaluate changes in tumor size in clinical trials. Volumetric analysis requires adherence to specific imaging recommendations. A 20% volume change was chosen to indicate a decrease or increase in tumor size. Use of these criteria in future trials will enable meaningful comparison of results across studies. CONCLUSIONS: The proposed imaging response evaluation guidelines, along with validated clinical outcome measures, will maximize the ability to identify potentially active agents for patients with NF and benign tumors.


Subject(s)
Clinical Trials as Topic/standards , Diagnostic Imaging/methods , Neurofibroma, Plexiform/therapy , Neurofibromatoses/therapy , Neuroma, Acoustic/therapy , Treatment Outcome , Clinical Trials as Topic/methods , Diagnostic Imaging/standards , Humans , Neurofibroma, Plexiform/diagnosis , Neurofibroma, Plexiform/etiology , Neurofibromatoses/complications , Neurofibromatoses/diagnosis , Neuroma, Acoustic/diagnosis , Neuroma, Acoustic/etiology , Tumor Microenvironment
19.
BMJ Case Rep ; 20132013 Oct 07.
Article in English | MEDLINE | ID: mdl-24099762

ABSTRACT

A middle-aged Chinese woman presented with a slowly enlarging mass over the right side of her face that was later proven histologically to be a plexiform neurofibroma. This was associated with a localised depression over her right temple. There were no other features of neurofibromatosis-1. The presentation and biological behaviour of plexiform neurofibromas are reviewed in this manuscript. Particular attention is paid to the interaction of plexiform neurofibromas with their surrounding structures, as well as the postulated mechanisms by which this occurs.


Subject(s)
Facial Neoplasms/diagnosis , Neurofibroma, Plexiform/diagnosis , Diagnosis, Differential , Diagnostic Imaging , Facial Neoplasms/pathology , Facial Neoplasms/therapy , Female , Humans , Middle Aged , Neurofibroma, Plexiform/pathology , Neurofibroma, Plexiform/therapy
20.
Am J Ophthalmol ; 155(6): 1089-1094.e1, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23453281

ABSTRACT

PURPOSE: To describe the visual outcomes and volumetric magnetic resonance imaging (3D MRI) in children with neurofibromatosis type 1 (NF1) and orbitotemporal plexiform neurofibromas. DESIGN: Multicenter retrospective case series. METHODS: Two institutions with dedicated NF1 clinical research programs queried their established clinical databases for children with orbitotemporal plexiform neurofibromas. Visual acuity, refractive error, ambylopia, and treatment history were abstracted. Extent of orbitotemporal plexiform neurofibroma involvement was assessed clinically and with 3D MRI analysis. Children with optic pathway gliomas or ocular causes of decreased visual acuity (ie, cataracts, glaucoma) other than strabismus or anisometropia were excluded. RESULTS: Twenty-one children met inclusion criteria (median age 8 years, range 0.33-23 years). Orbitotemporal plexiform neurofibroma location was classified as isolated eyelid (n = 6), eyelid and orbit (n = 7), orbit and temporal region (n = 7), or diffuse orbit (n = 1). Three subjects had bilateral orbital involvement. Amblyopia secondary to the orbitotemporal plexiform neurofibroma was present in 13 subjects (62%) and was caused by strabismus (n = 2, 10%), occlusion from ptosis (n = 9, 43%), or anisometropia (n = 9, 43%), or a combination of factors (n = 6, 29%). MRI-derived volumes were measured in 19 subjects (median 41.8 mL, range 2.7-754 mL). All subjects with amblyopia had orbitotemporal plexiform neurofibroma volumes greater than 10 mL. CONCLUSION: In our series, amblyopia occurs in more than half of NF1 children with orbitotemporal plexiform neurofibromas, most commonly because of ptosis and anisometropia. The 3D MRI analysis allowed for sensitive measurement of orbitotemporal plexiform neurofibroma size, and larger volumes were associated with development of amblyopia.


Subject(s)
Eyelid Neoplasms/physiopathology , Neurofibroma, Plexiform/physiopathology , Neurofibromatosis 1/physiopathology , Orbital Neoplasms/physiopathology , Visual Acuity/physiology , Adolescent , Child , Child, Preschool , Eyelid Neoplasms/diagnosis , Eyelid Neoplasms/therapy , Female , Humans , Imaging, Three-Dimensional , Magnetic Resonance Imaging , Male , Neurofibroma, Plexiform/diagnosis , Neurofibroma, Plexiform/therapy , Neurofibromatosis 1/diagnosis , Neurofibromatosis 1/therapy , Orbital Neoplasms/diagnosis , Orbital Neoplasms/therapy , Retrospective Studies , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...